Exeliom Biosciences
PrivateLast Round
Series A
Extension
Oct 21, 2025
Total Funding Raised
$28.98M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Exeliom Biosciences operates in Healthcare & Life Sciences and is based in Dijon. Its latest recorded funding round was a Series A Extension round in October 2025.
Exeliom Biosciences is a biotechnology company that develops microbiome-based immunotherapies using single bacterial strain drug candidates to treat inflammatory bowel diseases and cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Exeliom Biosciences Comparables
Compare Exeliom Biosciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Microbiotica | 83% | |
| MRM Health | 80% | |
| Vedanta Biosciences | 77% |
For institutional investors. Book with your work email.
Exeliom Biosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Oct 21, 2025 | ||||
| Grant | Mar 6, 2024 | ||||
| Grant | Nov 28, 2023 | ||||
| Series A Extension | Jul 3, 2023 | ||||
| Grant | Aug 3, 2020 | ||||
Grant | Aug 12, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Exeliom Biosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Forepont Capital Partners | Series A Extension |
| CE-Ventures | Series A Extension |
| UI Investissement | Series A Extension |
| Sofimac Innovation | Series A |
| National Research Institute for Agriculture, Food and Environment | Series A |
| Auriga Partners | Series A Extension, Series A |
| Capital Grand Est | Series A Extension, Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 27, 2026
Monthly visitors grew 288% MoM to 1.3K.
- Jul 10, 2025
Announced the launch of LIVEDIFF Part 2.
For institutional investors. Book with your work email.
Exeliom Biosciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Exeliom Biosciences's valuation, stock price, and market status.
Is Exeliom Biosciences a public or private company?
Exeliom Biosciences is a private company.
What is the current stock price of Exeliom Biosciences?
Exeliom Biosciences is a private company, so its shares have no public market price. Caplight tracks Exeliom Biosciences's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Exeliom Biosciences worth (valuation)?
Valuation information for Exeliom Biosciences is not publicly available.
Can I buy Exeliom Biosciences stock?
Exeliom Biosciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Exeliom Biosciences's last funding round?
Exeliom Biosciences's most recent funding round was Series A Extension on October 21, 2025.
Who are the main investors in Exeliom Biosciences?
Key investors in Exeliom Biosciences include CE-Ventures, Auriga Partners, CE-Ventures, Biocodex.
Will Exeliom Biosciences IPO soon?
No public IPO plans have been announced for Exeliom Biosciences.
How can I track Exeliom Biosciences secondary market activity?
Caplight tracks bids, offers, and trades in Exeliom Biosciences's shares on secondary markets.